Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALStandard

QNASL

BECLOMETHASONE DIPROPIONATE

Standard Dose
0.04MG/ACTUATION
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview QNASL is listed in Drugs@FDA under application 202813 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient BECLOMETHASONE DIPROPIONATE Form and strength AEROSOL, METERED;NASAL - 0.04MG/ACTUATION Sponsor TEVA BRANDED PHARM Submission history Latest submission status date: 2018-03-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview QNASL is listed in Drugs@FDA under application 202813 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient BECLOMETHASONE DIPROPIONATE Form and strength AEROSOL, METERED;NASAL - 0.04MG/ACTUATION Sponsor TEVA BRANDED PHARM Submission history Latest submission status date: 2018-03-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
QNASL (BECLOMETHASONE DIPROPIONATE) | Drug Monograph | MedicHelpline